Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80689 | 0.88 | PPARA (0.58) | PPARAGPR84DAOCA2DHODH | |
| SCHEMBL31181866 | 0.86 | PPARA (0.53) | PPARAGPR84DAOCA2DHODH | |
| SCHEMBL28183069 | 0.85 | PPARA (0.51) | PPARAGPR84DAOCA2DHODH | |
| SCHEMBL1044877 | 0.85 | PPARA (0.51) | PPARAGPR84DAOCA2DHODH | |
| SCHEMBL9852584 | 0.84 | PPARA (0.53) | PPARAGPR84DAOCA2DHODH | |
| SCHEMBL963834 | 0.83 | PPARG (0.53) | PPARAGPR84DAOEPHX2LTA4H | |
| SCHEMBL18643881 | 0.82 | PPARA (0.49) | PPARAGPR84DAOCA2DHODH | |
| SCHEMBL7729335 | 0.82 | GPR84 (0.59) | GPR84DAOCA2EPHX2LTA4H | |
| Hydrochloric Acid SCHEMBL7724235 | 0.81 | EPHX2 (0.48) | PPARAGPR84DAODHODHEPHX2 | |
| SCHEMBL30720055 | 0.79 | PPARA (0.50) | PPARAGPR84DAODHODHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616459-B1 | Polymeric coatings for fortification of visible, infrared, and laser optical devices | LOCKHEED MARTIN CORPORATION (US) | 2017-04-11 | — | — | US | claimed |
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4644398-A1 | SURFACE TREATMENT AGENT | Daikin Industries, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024172036-A1 | SURFACE TREATMENT AGENT | ダイキン工業株式会社 | 2024-08-22 | — | — | WO | disclosed |
| CN-117682973-A | Sulfonamide compound and medical application thereof | 中国药科大学 | 2024-03-12 | — | — | CN | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| EP-0718264-B1 | A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition | CHISSO CORP (JP) | 1999-11-17 | — | — | EP | disclosed |
| CN-1218460-A | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 1999-06-02 | — | — | CN | disclosed |
| EP-0893423-A1 | LIQUID CRYSTAL COMPOUNDS HAVING FLUORINATED LINKAGES, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAY DEVICES | CHISSO CORPORATION (JP) | 1999-01-27 | — | — | EP | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| US-5702641-A | ELECTRICAL AND CHEMICAL STABILITY | CHISSO CORPORATION (JP) | 1997-12-30 | — | — | US | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
| EP-0718264-A1 | A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition | Chisso Corporation (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | PPARA 219/4885GPR84 62/4885DAO 2857/4885 |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | PPARA 573/4885GPR84 1048/4885DAO 391/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | PPARA 1040/4885GPR84 26/4885DAO 1308/4885 |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | ITGA1, ITGB1, GDI1 | PPARA 3191/4885GPR84 815/4885DAO 1028/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | PPARA 333/4885GPR84 55/4885DAO 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.